Bio


My long-term goals involve the development of a full understanding of key molecular mechanisms and the identification of corresponding therapeutics for human diseases. My research training and academic experience have provided me with an excellent background necessary in multiple fields including molecular biology, cell biology, medicinal chemistry, and biochemical pharmacology. We first revealed a novel mechanism underscoring the regulation of metabolic profiles and mitochondrial function of epithelial cells by IL-22 during cell injury, which might provide useful insights from the bench to the clinic in treating and preventing more diseases, especially acute stroke/traumatic brain injuries. We subsequently demonstrated that autophagy was induced to play cytoprotective roles in numerous cells, which highlighted the potential therapeutic strategies for CNS neurodegeneration diseases or cancer by targeting autophagy. For my postdoctoral training, I continue to build on my previous researches in metabolic profiles and mitochondrial function regulations by concentrating on determining the role of mitochondrial thioredoxin metabolism in neuronal survival.

Professional Education


  • Ph.D., Fudan University (2019)

Stanford Advisors


  • Yang Hu, Postdoctoral Faculty Sponsor

All Publications


  • Gene therapy for neurodegenerative disorders: advances, insights and prospects ACTA PHARMACEUTICA SINICA B Chen, W., Hu, Y., Ju, D. 2020; 10 (8): 1347–59

    Abstract

    Gene therapy is rapidly emerging as a powerful therapeutic strategy for a wide range of neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD). Some early clinical trials have failed to achieve satisfactory therapeutic effects. Efforts to enhance effectiveness are now concentrating on three major fields: identification of new vectors, novel therapeutic targets, and reliable of delivery routes for transgenes. These approaches are being assessed closely in preclinical and clinical trials, which may ultimately provide powerful treatments for patients. Here, we discuss advances and challenges of gene therapy for neurodegenerative disorders, highlighting promising technologies, targets, and future prospects.

    View details for DOI 10.1016/j.apsb.2020.01.015

    View details for Web of Science ID 000567649600001

    View details for PubMedID 32963936

    View details for PubMedCentralID PMC7488363